Search alternatives:
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a large » _ large (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a large » _ large (Expand Search)
-
8161
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
8162
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
8163
-
8164
-
8165
Genetic characterization of <i>Mycoplasma pneumoniae</i> isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of <i>p1</i> gene ty...
Published 2019“…The remaining strain with an irregular typing pattern had a large deletion in the <i>p1</i> operon.</p></div>…”
-
8166
-
8167
CTS-treated MCF10A cell viability is time-dependent and serum-sensitive.
Published 2013“…<p>A) MCF10A (dashed line) cells incubated with 500 nM ouabain showed a time-dependent decrease in viability during CTS treatment. …”
-
8168
-
8169
-
8170
Entry probability as a function of and for .
Published 2009“…(c) When the initial and final states have larger degradation rates, a maximum as a function of arises for large . …”
-
8171
Bcl-2 family mRNA expression in IL-17A and IFN-γ-treated monocyte-derived DC.
Published 2013“…<p>(<b>A,B</b>) DC at day 0 (None) or treated 12 days with IL-17A +/− IFN-γ. …”
-
8172
-
8173
-
8174
-
8175
-
8176
-
8177
Photoinactivation of PSD-95-4c decreases GluR2 staining with no changes in NR1 or TfR staining.
Published 2013“…Only GluR2 in the FlAsH group showed a significant decrease (16% ±5 <i>n</i> = 7). (C) PSD-95-4c distribution was not changes after FALI. …”
-
8178
Local inhibition of nitrergic activity in tenotomized rats accelerates muscle regeneration by increasing fiber area and decreasing central core lesions
Published 2019“…<div><p>Muscular atrophy is a progressive degeneration characterized by muscular proteolysis, loss of mass and decrease in fiber area. …”
-
8179
-
8180
Plasma membrane localized KCa3.1 is decreased by DN Rab1 and Rab8, but not by Rab2 or Rab6.
Published 2014“…<p>HEK293 cells were co-transfected with BLAP-KCa3.1 and either WT, DA or DN Rabs 1, 2, 6 or 8 and plasma membrane localized KCa3.1 evaluated by specific biotinylation, streptavidin labeling and IB (see Methods). As shown in <b>A</b> and <b>C</b>, DN Rab8 (T22N) and two different DN Rab1s (N124I, S25N) decreased expression of plasma membrane KCa3.1. …”